WO1993003714A3 - Method for treatment of metabolic disorders - Google Patents
Method for treatment of metabolic disorders Download PDFInfo
- Publication number
- WO1993003714A3 WO1993003714A3 PCT/US1992/006536 US9206536W WO9303714A3 WO 1993003714 A3 WO1993003714 A3 WO 1993003714A3 US 9206536 W US9206536 W US 9206536W WO 9303714 A3 WO9303714 A3 WO 9303714A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- metabolic disorders
- administering
- animal
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92917697A EP0600973A1 (en) | 1991-08-27 | 1992-08-11 | A method for treatment of metabolic disorders and metabolism |
JP5504336A JPH06510760A (en) | 1991-08-27 | 1992-08-11 | Metabolic disorders and metabolic treatments |
AU24075/92A AU664710B2 (en) | 1991-08-27 | 1992-08-11 | A method for treatment of metabolic disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75005991A | 1991-08-27 | 1991-08-27 | |
US75056991A | 1991-08-27 | 1991-08-27 | |
US750,569 | 1991-08-27 | ||
US750,059 | 1991-08-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993003714A2 WO1993003714A2 (en) | 1993-03-04 |
WO1993003714A3 true WO1993003714A3 (en) | 1993-06-10 |
Family
ID=27115223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/006536 WO1993003714A2 (en) | 1991-08-27 | 1992-08-11 | Method for treatment of metabolic disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0600973A1 (en) |
JP (1) | JPH06510760A (en) |
AU (3) | AU664710B2 (en) |
CA (1) | CA2113817A1 (en) |
WO (1) | WO1993003714A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0599697A1 (en) * | 1992-11-24 | 1994-06-01 | Synthelabo | Pyrrole derivatives, their preparation and application in therapy |
FR2706899A1 (en) * | 1993-06-22 | 1994-12-30 | Synthelabo | Pyrrole derivatives, their preparation and their therapeutic application |
PT724435E (en) * | 1993-10-21 | 2002-11-29 | Searle & Co | UTEIS AMIDINE DERIVATIVES AS NITRIC OXIDE INHIBITORS |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5935927A (en) * | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
FR2719844B1 (en) * | 1994-05-10 | 1996-06-07 | Synthelabo | 5,6-dihydro-4h-thieno [3,4-c] pyrrole derivatives, their preparation and their therapeutic use. |
GB9511757D0 (en) * | 1995-05-19 | 1995-08-02 | Univ Strathclyde | Agents for reducing weight |
EP0912523A1 (en) * | 1996-05-21 | 1999-05-06 | PHARMACIA & UPJOHN COMPANY | Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus |
WO1999055321A1 (en) * | 1998-04-24 | 1999-11-04 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
KR20020009570A (en) * | 1999-03-05 | 2002-02-01 | 도리이 신이찌로 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE α4β2 RECEPTOR |
WO2001003680A2 (en) * | 1999-07-09 | 2001-01-18 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
AU2002221222A1 (en) * | 2000-12-04 | 2002-06-18 | Biovitrum Ab | Novel method and use |
SE0004462D0 (en) | 2000-12-04 | 2000-12-04 | Pharmacia Ab | Novel method and use |
GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
WO2004011440A1 (en) * | 2002-07-30 | 2004-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredint |
ITRM20020625A1 (en) | 2002-12-17 | 2004-06-18 | Sigma Tau Ind Farmaceuti | DERIVATIVES OF GUANIDINE VARIOUSLY REPLACED, THEIR USE AS MEDICATIONS WITH ANTI-DIABETIC AND / OR ANTIOBESITY ACTIVITY. |
US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
WO2006061992A1 (en) * | 2004-12-10 | 2006-06-15 | Ajinomoto Co., Inc. | Preventive/therapeutic composition for liver disease |
AU2006215703A1 (en) * | 2005-02-17 | 2006-08-24 | Instituto Del Metabolismo Celular, S.L. | L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism |
WO2007125385A2 (en) | 2005-12-22 | 2007-11-08 | Neurochem (International) Limited | Treatment of renal disorders, diabetic nephopathy and dyslipidemias |
EP2058008B1 (en) * | 2006-08-11 | 2013-08-21 | National University Corporation Nagoya University | Anti-obesity agent and use thereof |
DE102007004781A1 (en) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent |
GB0800383D0 (en) * | 2008-01-10 | 2008-02-20 | Univ Strathclyde | Weight reducing compounds |
WO2014061734A1 (en) * | 2012-10-18 | 2014-04-24 | 日清食品ホールディングス株式会社 | Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method |
GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
MX2016016480A (en) * | 2014-07-02 | 2017-08-02 | Inflectis Bioscience | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies. |
DE102016125414A1 (en) * | 2016-12-22 | 2018-06-28 | Bitop Ag | Composition containing N-acetyldiaminobutyric acid |
GB2609003A (en) * | 2021-07-15 | 2023-01-25 | Univ Nottingham Trent | Compounds and pharmaceutical compositions for the treatment of metabolic disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2673381B2 (en) * | 1990-02-23 | 1997-11-05 | 持田製薬 株式会社 | Pre-diabetes treatment agent and / or lipid lowering agent |
WO1991012799A1 (en) * | 1990-02-28 | 1991-09-05 | The Upjohn Company | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders |
-
1992
- 1992-08-11 CA CA002113817A patent/CA2113817A1/en not_active Abandoned
- 1992-08-11 WO PCT/US1992/006536 patent/WO1993003714A2/en not_active Application Discontinuation
- 1992-08-11 EP EP92917697A patent/EP0600973A1/en not_active Withdrawn
- 1992-08-11 JP JP5504336A patent/JPH06510760A/en active Pending
- 1992-08-11 AU AU24075/92A patent/AU664710B2/en not_active Ceased
-
1995
- 1995-09-14 AU AU30614/95A patent/AU3061495A/en not_active Abandoned
- 1995-09-14 AU AU30615/95A patent/AU3061595A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
CHEM. PHARM. BULL. vol. 18, no. 8, 1970, pages 1636 - 1642 FUJIHIRA,E., ET AL 'EFFECT OF LONG-TERM FEEDING OF TAURINE IN HEREDITARY HYPERGLYCEMIC OBESE MICE' * |
Also Published As
Publication number | Publication date |
---|---|
CA2113817A1 (en) | 1993-02-04 |
AU3061495A (en) | 1995-11-09 |
JPH06510760A (en) | 1994-12-01 |
AU664710B2 (en) | 1995-11-30 |
AU3061595A (en) | 1995-11-09 |
AU2407592A (en) | 1993-03-16 |
EP0600973A1 (en) | 1994-06-15 |
WO1993003714A2 (en) | 1993-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993003714A3 (en) | Method for treatment of metabolic disorders | |
CA2045885A1 (en) | Inhibition of mammalian muscle wasting and protein degradation by tetracyclines | |
AU609664B1 (en) | A method of treating premature ejaculation using sertraline | |
SG115193G (en) | Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus | |
CA2180535A1 (en) | A method for treatment of psoriasis, by omeprazole or related compounds | |
CA2204616A1 (en) | Ppar gamma antagonists for treating obesity | |
PL306590A1 (en) | Substituted heterocyclic carboxylamides, method obtaining them and their application as therapeutic agents | |
HUT59313A (en) | Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions | |
FR2685641B1 (en) | METHOD FOR CONTROLLING A HEART STIMULATOR IN THE EVENT OF A VENTRICULAR EXTRA-SYSTOLE. | |
WO1996015784A3 (en) | 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance | |
CA2071629A1 (en) | Use of insulin sensitizing agents to treat hypertension | |
CA2015838A1 (en) | Method of topically treating acne vulgaris | |
CA2108903A1 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
WO1992019211A3 (en) | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same | |
IL102807A0 (en) | Therapeutic compounds | |
AU1302388A (en) | Method of treating anxiety with tetrahydrobenz(c,d)indole-6- carboxamides | |
RU94045271A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition | |
GB9108629D0 (en) | Heterocyclic pharmaceutical compounds,preparation and use | |
CA2120319A1 (en) | Pharmaceutical for the treatment of skin disorders | |
IL125104A0 (en) | Agent for prophylaxis and treatment of diabetic complications | |
NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
AU6053496A (en) | The use of sertraline to treat post myocardial infarction patients | |
AU1855088A (en) | Treating agent for heart failure | |
HU905683D0 (en) | The treatment of drug dependence by using sertraline | |
GEP20032956B (en) | Miticide Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2113817 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992917697 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992917697 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 469716 Country of ref document: US Date of ref document: 19950606 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992917697 Country of ref document: EP |